Skip to main content
OpenTrials
Completed

NCT Number: NCT01157676

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

This is a multi-institutional, randomized trial evaluating oncologic, perioperative, and functional outcomes following two standard care procedures for radical cystectomy. The participants will have one of the standard care procedures as part of their care. The two procedures that will be followed are open radical cystectomy and robotic assisted radical cystectomy (RARC). Open cystectomy is considered to be the more traditional approach. While newer, RARC is considered to be equivalent to open surgery when it is performed by a trained robotics surgeon. The reported complication rates of RARC appear comparable to open surgery. This means there is no significant difference in the risk between the two standard procedures. However, despite these potential advantages, true comparison between the open and robotic technique with regards to long term cancer related and functional outcomes has not been accomplished because previous studies did not compare patients of equal health status. The researchers hope to learn whether or not patients undergoing RARC recover more quickly than or at the same rate as patients undergoing an open radical cystectomy while having non inferior cancer related outcomes. This study is funded by the National Institutes of Health (NIH).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic Arizona, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must have biopsy proven bladder cancer. Official pathology report reviewed at the participating institution is required.
  • Bladder cancer must be clinical stage T1-T4, N0-1, M0. (AJCC 7th edition) or refractory cis (carcinoma in situ).

Exclusion criteria

  • Inability to give informed consent.
  • Prior major abdominal and pelvic open surgical procedures that would preclude a safe robotic approach, as determined by the treating surgeon.
  • At the discretion of the treating surgeon, any pre-existing condition such as severe chronic obstructive pulmonary disease that precludes a safe initiation or maintenance of pneumoperitoneum over a prolonged period of time and during surgery.
  • Age <18 or >99 years.
  • Pregnancy.

Treatment and study plan

Open radical cystectomy

Procedure

Standard of care removal of urinary bladder.

Robotic assisted radical cystectomy

Procedure

Standard of care removal of urinary bladder using DaVinci robot.

DaVinci Robot

Device

DaVinci robotic surgical system.

Primary outcomes

  1. Percentage of Participants With 2-year Progression Free Survival (PFS)

    Time frame: 24 months

    Progression will be determined by the treating physician using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria based on radiographic or pathological evidence of disease progression or death from disease.

  2. Number of Participants With Positive Margins

    Time frame: At time of cystectomy, approximately 1 hour.

    Evaluated are the number of participants with positive surgical, bladder, and urethral margins. Positive margin is defined as presence of tumor cells at the edge of the dissected tissue.

  3. Number of Participants Requiring Lymph Node Dissection

    Time frame: At time of cystectomy, approximately 1 hour

    Evaluated are the number of participants requiring extended or standard lymph node dissection

  4. Quality of Life (QOL) Outcomes

    Time frame: at baseline, 3 month, and 6 months

    Functional Assessment of Cancer Therapy- Vanderbilt Cystectomy Index (FACT-VCI) scores range is 0-168 which is sum of physical, emotional, wellbeing, and FACTS Bl Cys. higher scores=better QOL.

  5. Number of Participants With Post-surgical Complications

    Time frame: 90 days post operative

    Post surgical complications will be evaluated using the Clavien grading system with scores ranging from 0-5 with the higher number indicating increased post-surgical complications.

  6. Amount of Estimated Blood Loss (EBL) in ml

    Time frame: At time of cystectomy, approximately 1 hour

    Perioperative measures such as EBL will be evaluated by measuring the amount of participant blood loss in ml.

  7. Number of Participants Requiring Blood Transfusion

    Time frame: At time of cystectomy, approximately 1 hour

    Number of participants requiring peri, intra, and post operative blood transfusion.

  8. Number of Days of Post Operative Length of Hospital Stay

    Time frame: Day 10 post surgery

    Number of days of post operative length of hospital stay will be evaluated

  9. Length of Operative Time

    Time frame: At time of cystectomy, approximately 1 hour

    Length of minutes of cystectomy procedure

  10. Laboratory Values

    Time frame: baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months

    Serum Hemoglobin (Hb) and Albumin will be reported in grams per deciliters (g/dL)

  11. Measures of Functional Independence as Assessed by the Activities of Daily Living (ADL) Questionnaire

    Time frame: baseline, 1 month , 3 months, 6 months

    Participant reported ADL questionnaire is a 7 item questionnaire with scores ranging from 7-21 with a lower score indicating increased independence.

  12. Percentage of Participants With 3-year Progression Free Survival (PFS)

    Time frame: 3 years

    Progression will be determined by the treating physician using the RECIST Version 1.1 criteria based on radiographic or pathological evidence of disease progression or death from disease.

  13. Quality of Life (QOL) Outcomes as Assessed by the Short Form 8 (SF-8) Questionnaire

    Time frame: baseline, 3 month, and 6 month

    The SF-8 consists of two component summary scores; physical (PCS) and mental component summary (MCS). They are scored by weighting each score to a norm-based scoring model. The total scores will be reported as a percentile with higher score indicating better quality of health.

  14. Total Number of Participants Requiring Intra-operative Fluid Requirement

    Time frame: At time of cystectomy, approximately 1 hour

    Total number of participants requiring Intra-operative fluid requirement. (blood+plasma+platelets) Note: In robotic group 1 participant received both plasma and platelets and 1 other received platelets in addition to blood transfusion. In the open group 5 participants received plasma in addition to blood transfusion.

  15. Total Postoperative Analgesic Requirements

    Time frame: At time of cystectomy, approximately 1 hour

    Total postoperative analgesic requirements in milli grams

  16. Creatinine Value.

    Time frame: baseline, 6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months

    Serum creatinine will be reported in milligrams per deciliters (mg/dL).

  17. Measures of Functional Independence as Assessed by the Instrumental Activities of Daily Living (IADL) Questionnaire

    Time frame: baseline, 1 month, 3 months, 6 months

    Participant reported IADL questionnaire is an 8 item questionnaire with scores ranging from 8-32 with a lower score indicating increased independence.

  18. Performance Related Measures of Functional Independence as Assessed by the Hand Grip Strength Test

    Time frame: baseline, 1 month, 3 months, 6 months

    The hand grip strength test is measured in kilograms of pressure using a handheld dynamometer.

  19. Performance Related Measures of Functional Independence as Assessed by the Time Up and Go (TUG) Walking Test

    Time frame: baseline, 1 month, 3 months, 6 months

    The TUG test is measured in seconds. Patients will be timed as they rise from a standard chair, walk 3 meters, turn, walk back, and sit again.

  20. Quality of Life (QOL) Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Vanderbilt Cystectomy Index (FACT-VCI) Questionnaire

    Time frame: baseline, 3 months, 6 months

    FACT-VCI consists of eight domains: Five subscale scores (physical wellbeing, social wellbeing, emotional wellbeing, functional wellbeing, and FACT for patients with Bladder Cancer following Cystectomy [FACT-BL-Cys]) and three derived scores (trial outcome index), FACT-General form (FACT-G), and FACT-BL-Cys Total.The ranges of scores for each domain are as follows: 0-28 for physical, social, and functional wellbeing; 0-24 for emotional wellbeing; 0-60 for FACT-BL-Cys; 0-116 for FACT-VCI Trial Outcome Index (sum of physical wellbeing, functional wellbeing, and FACT-BL-Cys scores); 0-108 for FACT-G (sum of physical, social, emotional, and functional wellbeing scores); and 0-168 for FACT-BL-Cys Total (sum of physical, social, emotional, and functional wellbeing scores, and FACT-BL-Cys).The higher score indicates increased wellbeing.

Secondary outcomes

  1. Cost

    Time frame: Day 7

    Fixed and variable costs associated with the procedure.

Sponsors and collaborators

Lead sponsor

University of Miami

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2011
Primary completion
2018
Study completion
2018
First posted
Jul 7, 2010
Registry last updated
Nov 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.